SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Phase 2 Completed 15 enrolled NCIC Clinical Trials Group National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well SB-715992 works in treating patients with locally advanced, recurrent, or metastatic liver cancer.

Timeline

Start: 2005-03-08
Primary completion: 2006-09-26
Completion: 2008-09-22

Publications

Results Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs. 2008 Jun;26(3):265-72. doi: 10.1007/s10637-007-9103-2. Epub 2008 Jan 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ispinesib	Unknown	18 mg/m2	Intravenous

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Summary

Timeline

Publications

Drugs

Indications